Adding a new medication to standard blood cancer treatment for young adults

This trial is testing whether adding ruxolitinib — a medication that targets specific genetic changes in leukemia cells — to standard chemotherapy works safely and effectively in adolescents and young adults with a subtype of acute lymphoblastic leukemia called Ph-like ALL. You would receive the medication alongside the chemotherapy drugs that are already standard treatment for this cancer. The goal is to see if this combination helps treat the disease better while remaining tolerable.

Acute lymphoblastic leukemia is a serious blood cancer, and some forms like Ph-like ALL are harder to treat than others. Researchers believe that this medication, which targets the specific genetic changes driving Ph-like ALL, may improve outcomes when combined with standard chemotherapy.